Precision medication management, not just prescribing
Medication Intelligence™ sits next to Digital MSE™ under Attunio Clinical Intelligence™. It turns the medication record into a living picture — tracking response, surfacing side-effect signals, mapping the dose timeline, layering in pharmacogenomics, and flagging adherence patterns. Every signal is a prompt for the clinician, never a decision. Try confirming and dismissing below.
Signals, not diagnoses
Objective deltas vs. the patient's own baseline — prompts to ask better questions, not conclusions.
Sourced & explainable
Every signal traces to wearables, check-ins, refills, labs, or PGx — no black-box scoring.
Clinician decides
Decision support, not autonomous prescribing. Nothing enters the summary until the clinician confirms it.
Medication Intelligence™
Clinical signals · confirm to include in summary
Current medications
- Adderall XR15 mg daily
- Sertraline50 mg daily
- Attention+21% vs. baseline
Attention improved +21%
On-task gaze up since titration
- Processing speed−46% vs. baseline
Speech latency improved
Avg response delay 2.4s → 1.3s
- Sleep−14% vs. baseline
Sleep down 14%
Wearable total sleep time falling
- Appetite↓ vs. baseline
Appetite reduced
Self-reported, 2 consecutive check-ins
Medication response tracking
Objective and subjective measures before and after a dose change, scored against this patient's own baseline — the heart of precision medication management.
Clinical Intelligence Insight: Objective improvement across mood, processing speed, and attention after dose initiation — consistent with treatment response.
Medication timeline
The longitudinal spine that Digital MSE™, wearables, labs, and symptom scores all overlay onto.
- Jan 2Started
Adderall XR 10 mg
- Jan 16Increased
Adderall XR → 15 mg
- Feb 8Added
Booster IR 5 mg (afternoon)
- Mar 1Reduced
Adderall XR → 10 mg (sleep)
Pharmacogenomics
Metabolism intelligence from the NeuroRx Panel™ — context for dosing and adverse-effect risk.
- CYP2D6Intermediate metabolizer
Atomoxetine: dose with caution
- CYP2C19Poor metabolizer
Slow SSRI clearance — start low
- COMTVal/Met
Variable stimulant response
- MTHFRC677T heterozygous
Consider L-methylfolate adjunct
Insight: Likely slow metabolizer of CYP2C19 substrates — increased adverse-effect risk on standard SSRI dosing. Consider starting low.
Model card
What Medication Intelligence™ does, and what it deliberately does not
What it does
- Tracks symptom & objective response across dose changes
- Surfaces possible side-effect signals from wearables and check-ins
- Maps the medication change log and overlays other signals
- Adds pharmacogenomic context for metabolism and dosing
What it does not claim
- No autonomous prescribing or dose recommendations
- No diagnosis or causal claim about side effects
- Not a substitute for clinical judgment or lab confirmation
Known limitations
- Adherence is inferred from indirect signals, not confirmed intake
- Wearable signals are noisy and context-dependent
- PGx informs risk, not certainty — phenotype ≠ outcome
Provenance & posture
- Every signal is sourced and scored against the patient's own baseline
- Each carries a confidence level and direction of change
- Confirm/dismiss actions are audit-logged
Illustrative concept only. Medication response, side-effect, adherence, and pharmacogenomic signals shown here are mock data to explore the clinician experience — not clinical guidance. Pharmacogenomic interpretation and medication decisions require validated testing and licensed clinical judgment.